Page results
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
This page explains what sperm banking is, how it works and how it can benefit you.
-
A new research study at UCLH and UCL will investigate how a rare type of blood cancer develops and what types of treatment may be effective for patients.
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
UCLH research manager Sarah Taylor has won a national leadership award for her work to develop and train research staff.
-
This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
An antibody treatment trialled at UCLH cuts the risk of developing symptomatic COVID-19 by 77%.
File results
-
FOI/2024/0581 - Weight management services/ bariatric surgery/ access to Wegovy
-
FOI/2024/0582 - SACT (systemic anti-cancer therapy) treatments for endometrial cancer
-
FOI/2024/0583 - National inpatient survey improvements/ night-time noise levels/ ward lighting/ mealtime support
-
FOI/2024/0584 - Immunology Hidradenitis Suppurativa (HS) treatments
-
FOI/2024/0586 - Subject Access Requests (SAR) and Freedom of Information (FOI) requests for 2023/24
-
FOI/2024/0587 - Colorectal cancer treatments
-
FOI/2024/0589 - SACT Cancer report/ Drug Patient Level Contract Monitoring (DrPLCM) report
-
FOI/2024/0594 - Implementation of Federated Data Platform (FDP) and procurement of data platforms
-
FOI/2024/0595 - Capital estate activity for 2020-2024
-
FOI/2024/0597 - Urothelial cancer treatments